The cytotoxic effects of IL-2 combined with different dosages of sorafenib on renal cellular carcinoma

VernacularTitle:白细胞介素-2联合不同剂量索拉菲尼对肾癌细胞的体内外杀伤效应的研究
Author: Benhe WU ; Yiao TAN ; Lingfeng SUN ; Shuhan LIU ; Linyu ZHOU
Publication Type:Journal Article
Keywords: Renal carcinoma cell; IL-2; Sorafenib; Comprehensive treatment
From: The Journal of Practical Medicine 2014;(19):3049-3052
CountryChina
Language:Chinese
Abstract: Objective To investigate the cytotoxic effects of IL-2 combined with different dosages of sorafenib on renal cellular carcinoma cell line 786-0. Methods Renal carcinoma cell 786-0 was cultured. Then , IL-2 (20 μmol/L) combined with different dosages of sorafenib (6.9, 13.8, 20.8 μmol/L) were used to treat tumor cell 786-0. The inhibitory effect on cell proliferation was determined by MTT assay. Cell apoptosis was measured by Annexin V-FITC kit. The tumor-bearing mice models were established and divided into four groups. Results The tumor cell growth was inhibited with the time-course correlation in all groups. In the 48-hour high doses group, the inhibitory rate was up to (74.67±1.87) %. The rates of cell proliferation inhibition and cell apoptosis were higher in the high dosages group than those in the other groups. Conclusions Immunotherapy combined with target therapy could significantly inhibit the growth of renal cellular carcinoma. But we should find a proper dosage, which could improve the clinical effect and reduce the adverse effect.